Q-omics provides the consensus-scored RPS20P15 profile across patient tissues and cancer cell-line models. RPS20P15 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPS20P15 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, RPS20P15 RNA expression shows 8,906 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, LIHC, and GBM as cancer lineages where RPS20P15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS20P15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS20P15 survival associations across molecular data types. RPS20P15 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS20P15 RNA expression–survival associations across cancer types. High RPS20P15 expression shows unfavorable associations in MESO, THCA, LIHC, LUSC and KIRC, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for RPS20P15 RNA expression.
This table summarizes RPS20P15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS20P15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS20P15 shows lower tumor expression in LUAD and THCA and higher tumor expression in LIHC and HNSC. The LIHC box plot shows higher RPS20P15 RNA expression in tumor versus normal tissue (log2 FC = +0.342, t-test p < 0.001).
This table shows molecular features associated with RPS20P15 in patient tissues and cancer cell lines. In patient samples, RPS20P15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
